Evaluating quality of life after surgery for advanced ovarian cancer
Official title: Assessment of Quality of Life After Low Anterior Resection or Visceral Peritoneal Stripping During cytOreDuctive surgerY for Advanced Ovarian Cancer Requiring Tumor Resection on the Rectosigmoid Colon: a Prospective Cohort Study
Run by Seoul National University Hospital · NCT05431530 · Data updated 2026-11-12
This study looks at how surgery for advanced ovarian cancer affects the quality of life and bowel function in patients after their operation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 108 (estimated) |
| Sponsor | Seoul National University Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | June 22, 2022 |
| Main results expected | May 31, 2027 |
| Study ends | May 31, 2027 |
| Registry record updated | June 27, 2023 |
| Trial ID | NCT05431530 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with newly diagnosed ovarian cancer or related conditions who are scheduled for cytoreductive surgery.
✕Probably not a fit
Patients who have previously undergone low anterior resection or have other significant gastrointestinal issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study assesses the incidence of low anterior resection syndrome and the overall quality of life in patients who have undergone cytoreductive surgery for advanced ovarian cancer. It focuses on individuals who require the removal of tumors from the rectum and sigmoid colon, which can lead to complications affecting bowel function. By monitoring these patients post-surgery, the study aims to gather data on their recovery and the challenges they face related to bowel control and daily living. The findings could provide valuable insights into patient care and management following such surgical interventions.
Why it matters
Potential benefit: If successful, this study could improve understanding of post-surgical quality of life and lead to better management strategies for patients with advanced ovarian cancer.
How similar studies have gone: While there have been studies on quality of life post-surgery for various cancers, this specific focus on low anterior resection syndrome in ovarian cancer is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Those with newly diagnosed ovarian cancer, fallopian tube cancer and primary peritoneal carcinomatosis who plan to undergo cytoreductive surgery and secondary cytoreductive surgery after neoadjuvant chemotherapy. * Patients with PCDS or rectal and sigmoid coloni tumor invasion suspected on the preoperative image and need resection of the tumor and clinical FIGO stage IIIB or higher * ECOG performance status : 0-2 * Age over 18 Exclusion Criteria: * Patient who underwent low anterior resection in the past * Past history of gastrointestinal malignant tumor except to ovarian cancer * Patient who have colostomy * Patient who underwent radiation therapy to abdominal or pelvic cavity * ECOG performance status over 3 * Patient taking opioid analgesics * Patient who have intellectual disability or dementia
Where it's running
-
Seoul National University Hospital
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Hee Seung Kim, MD/PhD — Seoul National University Hospital
- Study coordinator: Soo Jin Park, MD
- Email: soojin.mdpark@gmail.com
- Phone: +82-02-2072-2388
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.